The past week has seen a slew of Q2 earnings reports from medical device companies — and the picture overall hasn’t been pretty amid the COVID-19 pandemic. Still, medtech CEOs during their earnings calls said they’re starting to see some signs of hospital procedures recovering a bit even as the southern U.S. deals with a […]
Sorrento licenses COVID-19 saliva test
Sorrento Therapeutics (NSDQ:SRNE) announced that it entered into a licensing agreement with Columbia University for its COVID-19 saliva diagnostic test. The one-step diagnostic test is designed to detect SARS-CoV-2 (the virus causing coronavirus) in as little as 30 minutes from a sample of saliva. Developed by a team at Columbia, the test will be marketed […]
TriSalus touts data for pressure-enabled drug-delivery tech
TriSalus Life Sciences touted results today from a Phase Ib trial of its pressure-enabled drug-delivery tech for immunotherapy. The company reported that delivering a concentrated dose of CAR-T cells at the site of a solid tumor using its technology was safe and contributed to positive clinical results. Get the full story at our sister site, Drug […]
Sorrento Therapeutics wins FDA nod for post-shingles pain patch
Shares in Sorrento Therapeutics (NSDQ:SRNE) soared today after the company announced that the FDA approved its ZTlido lidocaine pain patch designed to treat patients with post-shingles neuralgia. The company resubmitted its application for ZTlido to the FDA last year after it was rejected by the U.S. regulatory agency in 2016. Get the full story at our sister site, Drug […]
Scilex seeks EU nod for ZTlido lidocaine patch
Sorrento Therapeutics (NSDQ:SRNE) subsidiary Scilex Pharmaceuticals said today that it filed a marketing authorization application seeking approval for its ZTlido lidocaine patch. The San Diego, Calif.-based company said it is pursuing a hybrid regulatory pathway with the Medicines and Healthcare Products Regulatory Agency in the U.K., which will serve as the lead review agency. The company also plans to file […]
Sorrento seeks FDA nod for lidocaine patch
Sorrento Therapeutics (NSDQ:SRNE) said today that its subsidiary Scilex Pharmaceuticals resubmitted the new drug application for its lidocaine patch, ZTlido, to the FDA. The San Diego, Calif.-based company is developing the drug-device product for the relief of pain associated with post-herpetic neuralgia. Get the full story at our sister site, Drug Delivery Business News.
Scilex touts head-to-head study of lidocaine pain-relief patch
Sorrento Therapeutics (NSDQ:SRNE) subsidiary Scilex Pharmaceuticals touted data today from a head-to-head clinical adhesion study of its ZTlido lidocaine patch, comparing it to the EU reference product, Versatis. ZTlido is a lidocaine patch in development for the treatment of post-herpetic neuralgia – a severe neuropathic pain condition that affects elderly people and patients who have […]
Scilex touts data for novel lidocaine patch
Sorrento Therapeutics (NSDQ:SRNE) subsidiary Scilex Pharmaceuticals said today that its lidocaine patch, ZTlido, met primary and secondary endpoints in a pivotal study comparing the patch to Endo Pharmaceutical‘s Lidoderm patch. The data will be used to resubmit a new drug application to the FDA in mid-2017, the Malvern, Pa.-based company said. The clinical trial evaluated Scilex’s […]
